Eyepoint, Inc. · NASDAQ:EYPT

Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (October 2024)

44 slides from Eyepoint's investor presentation, Oct 28, 2024

  1. Slide 1: Investor Presentation October 2024

    Investor Presentation October 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate

  3. Slide 3: Committed to Developing Innovative Therapeutics for Serious Retinal Diseases

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 3 Committed to Developing Innovative Therapeutics to Improve the Lives of Patients with Serious Retinal Diseases

  4. Slide 4: Clinical Stage Biotech Company Pursuing Multi-Billion-Dollar Markets

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 3 Clinical Stage Biotech Company Pursuing Multi-Billion-Dollar Markets DURAVYU™ (vorolanib intravitreal insert) Multi-billion-dollar market opportunities Proprietary Durasert E™ IVT drug delivery ~$253.8 M of cash and investments on Sep

  5. Slide 5: Potential Multi-Billion-Dollar Product Opportunities Leveraging Durasert E

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. wet AMD, wet age-related macular degeneration; FPD, first patient dosed; DME, diabetic macular edema; GA, geographic atrophy Potential Multi-Billion-Dollar Product Opportunities Leveraging Bioerodible Durasert E™ Drug Delivery Technology Dura

  6. Slide 6: Bioerodible Durasert E Technology

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. IVT, intravitreal Bioerodible DURASERT E™ TECHNOLOGY Sustained-Release Drug Delivery with favorable safety profile Delivered via a standard in-office IVT injection Continuous dosing Zero-order kinetics drug release Durasert E™: bioerodible Dr

  7. Slide 7: Vorolanib is a Potent and Highly Selective Pan-VEGF Receptor Inhibitor

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. Sophie Bakri, M.D., et al. PLOS ONE, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0304782, 2024. VEGF(R), vascular endothelial growth factor (receptor); TKI, tyrosine kinase inhibitor; PDGF(R), platelet-derived growth

  8. Slide 8: DURAVYU: Vorolanib in Bioerodible Durasert E

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Solid insert is 94% drug and is only 1/5000 of vitreous volume Immediately bioavailable – reaches therapeutic levels in target tissues within hours Constant dosing – zero-order kinetics release for at least six months Controlled drug release

  9. Slide 9: DURAVYU Demonstrated Positive Clinical Activity and Favorable Safety Across Trials

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU Demonstrated Positive Clinical Activity and Favorable Safety Profile Across Multiple Clinical Trials and Indications 1. Interim data as of October 1, 2024. Preliminary data which may differ from future results of the same trial, or di

  10. Slide 10: Phase 2 VERONA Clinical Trial in DME – 16-Week Interim Results

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 VERONA Clinical Trial in DME – 16-Week Interim Results all patients Have completed the week 16 visit DME, diabetic macular edema Interim data as of October 1, 2024. Preliminary data which may differ from future results of the same tri

  11. Slide 11: Phase 2 VERONA Randomized, Open-Label, Aflibercept Controlled Trial

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DME, diabetic macular edema; VEGF, vascular endothelial growth factor; BCVA, best corrected visual acuity; OCT, optical coherence tomography; CST, central subfield thickness DURAVYU dosing Visit Scheduled aflibercept injection Sham injection

  12. Slide 12: VERONA Supplemental Injection Anti-VEGF Criteria

    VERONA Clinical Trial Supplemental Injection Anti-VEGF Criteria After Initial Dosing ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. vs. best on study measurement; 2. as measured by Spectral domain OCT (SD-OCT) BCVA, best corrected visual acuity; CST, central subfield thickness Starting

  13. Slide 13: Positive Interim Data Supports DURAVYU as a Potential Treatment for DME

    Positive Interim Data Supports DURAVYU as a Potential Treatment for DME Data support potential for vision improvement in DME as well as superior dosing intervals ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2.7MG EFFICACY 16-Week Results: Early and sustained BCVA improvement Ear

  14. Slide 14: Baseline BCVA and CST Demonstrate Patients with Active DME

    Baseline BCVA and CST Demonstrate Patients with Active DME (CST >325μm) ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Aflibercept 2mg (n=6) DURAVYU 1.3mg (n=10) DURAVYU 2.7mg (n=11) Mean BCVA, ETDRS letters (range) 67.5 (57-73) 66.9 (53-75) 65.5 (46-75) Mean CST, μm (range) 400.3 (341-46

  15. Slide 15: DURAVYU 2.7mg Clinically Meaningful Improvement in BCVA at 16 Weeks

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2.7mg Demonstrated Clinically Meaningful Improvement in BCVA at 16 Weeks ~Six Letters Better vs. Aflibercept Control DURAVYU 2.7mg +5.7 Mean Change in BCVA vs Aflibercept DURAVYU 1.3mg +0.6 +3.8 +8.9 +3.2 MEAN CHANGE IN BCVA FROM BASE

  16. Slide 16: Improved and Controlled Anatomy with DURAVYU 2.7mg

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Improved and Controlled Anatomy Demonstrated with DURAVYU 2.7mg and Mirror BCVA Results ~38 Microns Improved vs. Aflibercept Control Mean Change in CST vs Aflibercept DURAVYU 1.3mg -8.5 um -39.0 um -68.1 um -30.5 um MEAN CHANGE IN CST FROM BA

  17. Slide 17: Greater Proportion of Supplement-Free Eyes vs. Aflibercept Control

    Eyes Treated with DURAVYU had a Greater Proportion of Supplement-Free Eyes vs. Aflibercept Control at 16 Weeks ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Summary of Cumulative Supplement-Free Rates by Week* 100% 100% 100% *Time to aflibercept supplementation and supplement rates will

  18. Slide 18: Positive Interim Data for Ongoing Phase 2 VERONA Clinical Trial

    Positive Interim Data for Ongoing Phase 2 VERONA Clinical Trial – Data support potential for vision improvement in DME as well as superior dosing intervals ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2.7mg demonstrated an early and sustained improvement in both BCVA and CST 2.7

  19. Slide 19: Phase 2 DAVIO Positive Results in wet AMD

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 DAVIO 2 Positive Results in wet AMD A NON-INFERIORITY TRIAL VERSUS AN AFLIBERCEPT CONTROL

  20. Slide 20: DAVIO Randomized, Double-Masked, Aflibercept Controlled Clinical Trial

    DAVIO 2 is Randomized, Double-Masked, Aflibercept Controlled* Clinical Trial to Assess Efficacy and Safety of DURAVYU at Two Doses ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Aflibercept on-label control required by FDA -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 DURAVYU 2

  21. Slide 21: DURAVYU Statistically Non-Inferior in BCVA Change vs. Aflibercept

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU was Statistically Non-Inferior in Change in BCVA Compared to the Aflibercept Control *Blended week 28 and week 32 change vs. baseline **Month 8 represents 6 months after DURAVYU injection 1 – AAO 2022 presentation, Paolo Lanzetta, on

  22. Slide 22: Meaningful Reduction in Treatment Burden for Wet AMD

    DURAVYU Demonstrated a Meaningful Reduction in Treatment Burden as a Potential Maintenance Treatment For Wet AMD ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2mg DURAVYU 3mg Mean number of injections (week 8 through week 32) 0.55 0.73 Mean number of injections 6 months prior to

  23. Slide 23: Reduction in Treatment Burden vs. Aflibercept Control Arm

    DURAVYU also Demonstrated a Meaningful Reduction in Treatment Burden When Measured Prospectively vs. the Aflibercept Control Arm ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2mg DURAVYU 3mg Aflibercept 2mg q8W Mean number of injections week 8 through week 32 0.55 0.73 3.04 Reduc

  24. Slide 24: Nearly Two-Thirds of Eyes Supplement-Free up to Six Months

    Nearly Two-Thirds of Eyes Treated with DURAVYU were Supplement-Free up to Six-Months after Treatment ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *First visit patients are eligible to be supplemented **Month 8 represents 6 months post DURAVYU injection EOM, every-other-month Summary of

  25. Slide 25: DURAVYU 2mg Reduced Treatment Burden by 89%

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2mg Dose Reduced Treatment Burden by 89% Compared to Prior 6 Months Injections in year prior and during the DAVIO 2 trial DURAVYU 3 mg (n = 52) DURAVYU 2 mg (n = 50) Anti-VEGF injection Aflibercept loading dose Aflibercept + DURAVYU N

  26. Slide 26: DURAVYU 3mg Reduced Treatment Burden by 85%

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Injections in year prior and during DAVIO 2 trial DURAVYU 3 mg (n = 52) DURAVYU 2 mg (n = 50) Anti-VEGF injection Aflibercept loading dose Aflibercept + DURAVYU No injection Missed Visit Supplemental injection DURAVYU 3mg Dose Reduced Treatme

  27. Slide 27: DAVIO 2 Data Demonstrates Strong Anatomic Control

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Month 8 represents 6 months after first DURAVYU injection DAVIO 2 Data Demonstrates Strong Anatomic Control for DURAVYU DURAVYU 2mg +12.4 Mean Change in CST vs Aflibercept DURAVYU 3mg +5.2 +10.6 um +17.8 um +5.4 um MEAN CHANGE in CST Afliber

  28. Slide 28: DAVIO Met All Primary and Secondary Endpoints

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU Phase 2 DAVIO 2 Clinical Trial in Wet AMD Met All Primary and Secondary Endpoints Endpoint 2mg 3mg R Primary: Non-inferior change in BCVA vs. aflibercept - 0.3 letters - 0.4 letters R Secondary: Favorable safety profile1 No DURAVYU-re

  29. Slide 29: DAVIO Sub-Group Analysis of Patients Supplement-Free Up to 6 Months

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 DAVIO 2 Clinical Trial in Wet AMD Sub-Group Analysis of Patients Anti-VEGF Supplement-Free Up to 6 Months

  30. Slide 30: Numerically Better Visual Acuity in Supplement-Free Sub-Group

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Blended week 28 and week 32 change vs. baseline **Month 8 represents 6 months after DURAVYU injection DURAVYU Treated Patients had Numerically Better Visual Acuity vs. Aflibercept On-Label Control Patients in Supplement-Free Sub-Group DURAVY

  31. Slide 31: Strong and Sustained Anatomic Control in Supplement-Free Sub-Group

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Month 8 represents 6 months after first DURAVYU injection DURAVYU Treated Patients had Strong and Sustained Anatomic Control vs. Aflibercept On-Label Control Patients in Supplement-Free Sub-Group DURAVYU 2mg +2.6 Mean Change in CST vs Aflibe

  32. Slide 32: Phase 2 DAVIO Clinical Trial 12-Month Results in wet AMD

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 DAVIO 2 Clinical Trial 12-Month Results in wet AMD A NON-INFERIORITY TRIAL VERSUS AN AFLIBERCEPT CONTROL

  33. Slide 33: Nearly Identical BCVA Change Compared to Aflibercept Through 12 Months

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU Treated Patients had Nearly Identical BCVA Change Compared to Aflibercept On-Label Through 12-Months; Statistically Significant (95% CI) DURAVYU 2mg +0.4 Mean Change in BCVA vs Aflibercept DURAVYU 3mg +0.0 -0.5 -0.1 -0.5 MEAN CHANGE I

  34. Slide 34: Strong Anatomic Control Through Month 12

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU Treated Patients Showed Strong Anatomic Control Through Month 12 DURAVYU 2mg +10.0 Mean Change in CST vs Aflibercept DURAVYU 3mg -0.1 +11.1 um +21.2 um +11.2 um MEAN CHANGE in CST Aflibercept Aflibercept Aflibercept Aflibercept Aflibe

  35. Slide 35: Clinically Meaningful Supplement-Free Rates

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *First visit patients are eligible to be supplemented EOM, every-other-month DURAVYU Treated Patients had Clinically Meaningful Supplement-Free Rates Summary of Supplement-Free Rates by Month 100% 100% 100% Aflibercept Aflibercept Aflibercept

  36. Slide 36: Favorable Safety Profile Through Month 12

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. As deemed by the investigator SAE, serious adverse event; AE, adverse event; IVT, intravitreal injection DURAVYU Demonstrated a Favorable Safety Profile Through Month 12 No DURAVYU-related ocular or systemic SAEs1 No insert migration into

  37. Slide 37: Phase 3 Pivotal Trials Design

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 3 Pivotal Trials Design NON-INFERIORITY VERSUS AN AFLIBERCEPT CONTROL

  38. Slide 38: Phase 3 Trials Designed to Enable Global Regulatory Approval of DURAVYU

    Phase 3 Trials are Designed to Enable Global Regulatory Approval of DURAVYU ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Demonstrate DURAVYU, when administered every six months, achieves similar visual outcomes to on-label aflibercept while reducing treatment burden ~400 patients per tr

  39. Slide 39: DURAVYU in Wet AMD Phase 3 Pivotal Trial Design

    DURAVYU™ in Wet AMD Phase 3 Pivotal Trial Design ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Screening D1 W4 W8 W12 W16 W24 W32 W84-W92 W20 W28 DURAVYU™ 2.7mg Aflibercept 2mg q8W RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION VISIT VISIT SCHEDULED DURAVYU™ DOSE AFLIBERCEPT q8W 1⁰ ENDPOIN

  40. Slide 40: Commercial Manufacturing Facility

    Commercial Manufacturing Facility ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. FDA, Federal Drug Administration; EMA, European Medicines Agency Conveniently located in Northbridge, MA, near EyePoint headquarters Built to US FDA and EU EMA standards 40,000sf cGMP manufacturing facility B

  41. Slide 41: EYP-2301: Razuprotafib in Durasert E

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. EYP-2301: razuprotafib in Durasert E™ A sustained delivery tie-2 agonist for severe retinal diseases

  42. Slide 42: EYP-2301 is a Patented TIE-2 Agonist as a Potential New MOA

    EYP-2301: Razuprotafib in Durasert E™ is a Patented TIE-2 Agonist as a Potential New MOA for Treating Serious Retinal Diseases ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. Heier et al. Retina, 2021;41:1-19. and Joussen et al. Eye 2021; 35:1305-1316.; 2. Hammes, et. Al – Diabetes.2011

  43. Slide 43: On Track for Continued Execution and Well-Funded Through Key Milestones

    On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DME, diabetic macular edema; EOP2, End of Phase 2; wet AMD, wet age-related macular degeneration; SAB, Scientific Advisory Board DURAVYU™ Corporate ✓

  44. Slide 44: Investor Presentation October 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

    Investor Presentation October 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint Pharmaceuticals — Investor Presentation (October 2024) on 6ix